文献速递艾滋病与性传播感染病毒性肝炎

病毒复制与肝纤维化对HIV-HBV共感染者全因死亡率的影响:15年纵向队列回顾分析

Effect of Viral Replication and Liver Fibrosis on All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis B Virus-Coinfected Individuals: A Retrospective Analysis of a 15-Year Longitudinal Cohort.
PubMed 文献 · Clin Infect Dis · 2022-01-01

该研究前瞻性随访300例接受ART的HIV-HBV共感染者,中位10.5年,42例死亡。含TDF方案比例从基线18.7%升至随访末79.1%,HBV-DNA不可测比例从36.7%升至94.8%。HBV-DNA载量、时间平均累积HBV-DNA及基线晚期肝纤维化与全因死亡率独立相关,而HIV-RNA复制无显著关联。

要点

  • HBV-DNA载量每增加1 log10 IU/mL,全因死亡风险aHR=1.41(95%CI 1.04-1.93,P=.03)。
  • 基线晚期肝纤维化与死亡风险升高相关(aHR=2.35,95%CI 1.16-4.76,P=.02)。
  • HIV-RNA复制与全因死亡率无显著关联。

核心结论

  • 在接受含TDF方案为主的HIV-HBV共感染者中,当前及既往HBV复制和肝纤维化是全因死亡率的重要驱动因素。
  • HBV-DNA和肝纤维化仍是该人群的重要预后指标。

研究设计与样本

  • 前瞻性随访300例接受ART的HIV-HBV共感染者,基线及每6-12个月采集病毒学和临床数据。
  • 采用联合纵向生存模型分析HBV-DNA、HIV-RNA和肝纤维化与全因死亡率的风险关联。

主要发现

  • 主要死因为非AIDS/非肝相关恶性肿瘤(28.6%),其次为肝相关(16.7%)、AIDS相关(16.7%)和其他(16.7%)。
  • HBV-DNA载量(aHR每log10 IU/mL=1.41,95%CI 1.04-1.93,P=.03)和时间平均累积HBV-DNA(aHR每log10拷贝年=1.37,95%CI 1.03-1.83,P=.03)与全因死亡率相关。
  • 基线晚期肝纤维化与死亡率升高相关(aHR=2.35,95%CI 1.16-4.76,P=.02)。
  • HIV-RNA复制与死亡率无显著关联。

临床怎么用

  • 对HIV-HBV共感染者应持续监测HBV-DNA和肝纤维化,作为预后评估的重要组成部分。
  • 即使接受含TDF方案,仍需关注HBV复制和肝纤维化对死亡风险的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In individuals living with human immunodeficiency virus (HIV) and hepatitis B virus (HBV), widespread tenofovir (TDF)-containing antiretroviral therapy (ART) has led to substantial decreases in HBV-DNA and HIV-RNA detection. However, the links between viral replication, liver fibrosis, and mortality remain unclear. METHODS: A total of 300 individuals living with HIV-HBV and undergoing ART were prospectively followed. Virological and clinical data were obtained at baseline and every 6-12 months. We quantified the associations between HBV-DNA, HIV-RNA, and liver fibrosis with risk of all-cause mortality using a joint longitudinal survival model. Viral detection, viral loads, and time-averaged cumulative viral loads of HIV and HBV were modeled as 3 separate exposures. RESULTS: During a median of 10.5 years (interquartile range, 4.0-14.6), the proportion undergoing TDF-containing ART (baseline = 18.7%, end of follow-up = 79.1%) and with undetectable HBV-DNA (baseline = 36.7%, end of follow-up = 94.8%) substantially increased. 42 participants died (incidence rate = 1.30/100 person-years, 95% confidence interval [CI] = .96-1.76). The leading causes of death were non-AIDS/non-liver-related malignancies (28.6%), followed by liver-related (16.7%), AIDS-related (16.7%), and other (16.7%). All-cause mortality was associated with HBV-DNA viral load (adjusted hazards ratio [aHR] per log10 IU/mL = 1.41, 95% CI = 1.04-1.93, P = .03) or time-averaged cumulative HBV-DNA (aHR per log10 copy-years = 1.37, 95% CI = 1.03-1.83, P = .03), but not undetectable HBV-DNA. Advanced liver fibrosis at baseline was also associated with increased mortality rates (aHR = 2.35, 95% CI = 1.16-4.76, P = .02). No significant association between HIV-RNA replication and mortality was observed. CONCLUSIONS: Concurrent and historical HBV replication and liver fibrosis are important drivers of all-cause mortality in largely TDF-treated individuals living with HIV-HBV, despite one-fifth of deaths being liver-related. HBV-DNA and liver fibrosis remain important prognostic indicators for this patient population.

来源:Clin Infect Dis,查看原文。版权归原作者所有。

引用

  1. Dezanet LNC, Kassime R, Miailhes P, et al. Effect of Viral Replication and Liver Fibrosis on All-Cause Mortality in Human Immunodeficiency Virus-Hepatitis B Virus-Coinfected Individuals: A Retrospective Analysis of a 15-Year Longitudinal Cohort. Clin Infect Dis. 2022. PMID: 34197574. doi:10.1093/cid/ciab594

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。